版本:
中国

BRIEF-Beigene presents initial phase 1 data on BTK inhibitor BGB-3111

June 16 Beigene Ltd

* Beigene presents initial phase 1 data on BTK inhibitor BGB-3111 combined with Obinutuzumab at the 14th international conference on malignant lymphoma and announces additional planned global registrational trials for BGB-3111

* ‍Only one patient discontinued treatment due to an AE, squamous cell carcinoma (SCC), and this patient had a prior history of SCC​

* Initial phase 1 data demonstrate that combination is well tolerated Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐